Guanfacine for PONV and Pain After Sinus Surgery
| Status: | Completed |
|---|---|
| Conditions: | Post-Surgical Pain, Hospital |
| Therapuetic Areas: | Musculoskeletal, Other |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 1/5/2019 |
| Start Date: | November 2016 |
| End Date: | February 2017 |
Postoperative nausea and vomiting (PONV) and pain are the most common causes of Post
Anesthesia Care Unit (PACU) discharge delay, with untreated PONV occurring in 20-30% of
post-surgical patients. The effect of guanfacine (GF) administration on pain and nausea
scores will be assessed with two groups. One group will receive 1 mg of GF to take orally and
the other group will receive a similar appearing placebo (containing no drug) to take orally.
Anesthesia Care Unit (PACU) discharge delay, with untreated PONV occurring in 20-30% of
post-surgical patients. The effect of guanfacine (GF) administration on pain and nausea
scores will be assessed with two groups. One group will receive 1 mg of GF to take orally and
the other group will receive a similar appearing placebo (containing no drug) to take orally.
Pain after surgery is commonly treated with narcotics which can potentiate PONV, further
delaying PACU discharge. In multiple studies, alpha-2 agonists such as clonidine and
dexmedetomidine reduce both the incidence of PONV and post-op pain, as well as requirements
for postoperative analgesics. These actions are mediated via central alpha-2A receptors
(A2AR). Of the A2AR agonists, guanfacine, though a weak antihypertensive agent, has the
highest selectivity for the A2AR, but to date is untested for its potential to treat either
PONV or post-operative pain.
delaying PACU discharge. In multiple studies, alpha-2 agonists such as clonidine and
dexmedetomidine reduce both the incidence of PONV and post-op pain, as well as requirements
for postoperative analgesics. These actions are mediated via central alpha-2A receptors
(A2AR). Of the A2AR agonists, guanfacine, though a weak antihypertensive agent, has the
highest selectivity for the A2AR, but to date is untested for its potential to treat either
PONV or post-operative pain.
Inclusion Criteria:
- VUMC patients undergoing sinus surgery in MCE OR
Exclusion Criteria:
- Inability to read and freely consent
- Patients who take alpha-2 agonists routinely (guanfacine, clonidine, tizanidine)
- Patients undergoing sinus surgery planned for greater than 3 hours
- Patients with significant pre-existing pain, on chronic pain (opioid, methadone)
therapy, severe fibromyalgia or other pre-existing pain condition in any body part
- Patients with preoperative nausea/vomiting at baseline.
- Pregnant or lactating women
We found this trial at
1
site
1211 Medical Center Dr
Nashville, Tennessee 37232
Nashville, Tennessee 37232
(615) 322-5000
Vanderbilt Univ Med Ctr Vanderbilt University Medical Center (VUMC) is a comprehensive healthcare facility dedicated...
Click here to add this to my saved trials
